We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03463954
Recruitment Status : Not yet recruiting
First Posted : March 13, 2018
Last Update Posted : March 3, 2021
Information provided by (Responsible Party):
Novian Health Inc.

Brief Summary:
Prior to this confirmatory pivotal study, the multicenter Br-002 feasibility study was completed. 98% of tumors less than or equal to 15mm were completely ablated in one procedure.This study will evaluate Novilase for the focal destruction of malignant tumors of the breast that are less than or equal to 15 mm against a performance goal for the standard of care, lumpectomy. The ASBrS' goal of less than 20% retreatment by 2020 was selected as a representative performance goal, i.e., 80.0%, and is consistent with published effectiveness rates for lumpectomy.

Condition or disease Intervention/treatment Phase
Malignant Neoplasm of Breast Device: Novilase Laser ablation Not Applicable

Detailed Description:
Subjects with biopsy-diagnosed malignant breast tumors less than or equal to 15 mm will be invited to participate. Subjects will receive a screening MRI and if eligible will then have laser ablation, followed by MRI and an excision at 4-6 weeks following the laser procedure. This study will be deemed successful if the lower limit of a 95% confidence interval for the proportion of patients who have complete tumor ablation with one Novilase laser ablation procedure at 4-6 weeks post-procedure is greater than the performance goal. Specifically, Novilase will have demonstrated success if the complete tumor ablation rate is greater than 87.85%.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 122 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Prospective, Multicenter Confirmatory Clinical Evaluation of Novilase® Interstitial Laser Therapy for the Focal Destruction of Malignant Breast Tumors ≤15 mm (BR-003)
Estimated Study Start Date : August 2021
Estimated Primary Completion Date : October 2022
Estimated Study Completion Date : December 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Experimental: Novilase Laser Ablation and excision
Eligible subject will receive image-guided laser ablation of a targeted malignant breast tumor. At 4-6 weeks following the ablation, she will receive a MRI and excision. Pathology and MRI will determine rate of complete ablation. Subject is expected to proceed with radiation and/or adjuvant therapy per standard of care.
Device: Novilase Laser ablation
Image-guided, percutaneous laser ablation of breast tumors

Primary Outcome Measures :
  1. Percentage of target tumors completely ablated in one procedure [ Time Frame: 4-6 weeks ]
    Efficacy: Rate of complete ablation by Novilase laser ablation

  2. Frequency of adverse events (categorized using the NCI Common Terminology for Adverse Events (CTCAE) v4.0 guidelines) post-laser ablation and post-surgery [ Time Frame: 4-6 weeks ]
    Safety: frequency of AEs

Secondary Outcome Measures :
  1. Patient reported rate of return to activities of daily living post-laser ablation and post-surgery [ Time Frame: 4-6 weeks ]
    Rate of recovery

  2. Physician reported cosmetic satisfaction, utilizing the 4-point scoring system of breast cosmesis in protocol (e.g., excellent, good, fair, poor) post-laser ablation and post-surgery (4-6 weeks) [ Time Frame: 4-6 weeks ]
    Post-procedure cosmetic satisfaction

  3. Health related quality of life outcome measures at three timepoints via EORTC QLQ-C30 & QLQ-BR23 questionnaire (baseline and 4-6 weeks post-laser ablation and post-surgery) [ Time Frame: 4-6 weeks ]
    Health-related quality of life outcome measures

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Females, aged 18 years and older
  • Able to give written informed consent herself
  • Definitive pathologic diagnosis by needle core biopsy
  • Unifocal malignant tumor (T1a-c, N0-1, M0) that does not exceed 15 mm in longest dimension and measures at least 5 mm away from the skin and chest wall, or can be moved at least 5 mm away from the skin and chest wall by injection of saline or local anesthetic
  • No more than 10 mm of calcifications confined to the tumor on imaging
  • Tumor is well visualized through ultrasound or x-ray mammography imaging and amenable to image-guidance therapy (i.e., a tumor which is well visualized through imaging can be identified from surrounding breast tissue and does not have margins obscured by other structures or artifacts on the images)
  • Tumor is well visualized on MRI
  • Subject with mammographic appearance of overall dense parenchymal tissue may be included, as long as a clearly evident marker is present at tumor site
  • Tumor with less than 25% intraductal component, as determined by core biopsy
  • No clinically significant co-morbidities (e.g., chronic illnesses existing simultaneously with and usually independent of breast cancer) that affect life expectancy
  • Subject weight limited to ≤300 lbs. or ≤136 kg
  • Subject agrees to comply with standard of care radiation or adjuvant therapy as prescribed by physician

Exclusion Criteria:

  • Subject younger than 18 years of age
  • Pregnant or breast-feeding
  • Tumor poorly visualized by ultrasound or x-ray mammography imaging
  • Contraindications to administration of gadolinium-based contrast agent, including: prior allergic reaction to a gadolinium-based contrast agent, moderate to end-stage kidney disease, and/or acute or chronic severe renal insufficiency (Glomerular filtration rate (GFR) <30ml/min/1.73 sq. meters)
  • Contraindications to MRI according to site guidelines (e.g., cardiac pacemaker, metallic implants)
  • History of severe asthma
  • Tumor measuring greater than 15 mm in longest dimension
  • Microcalcifications that extend beyond target tumor such that overall longest dimension of target tumor and calcifications is longer than 15 mm.
  • Advanced stage breast cancer
  • Tumors that are lobular neoplasm, metastatic carcinoma to breast, sarcoma, Phyllodes tumor, or Paget's disease
  • Tumor with only DCIS with microinvasion
  • Extensive intraductal component in lesion (i.e., >25%) as determined by core biopsy
  • Subject who is known to be BRCA positive
  • Tumor that is ER/PR/HER2 negative (TNBC)
  • Inability to lie in prone or supine position for one hour
  • Subject who is currently participating in another investigational treatment, device or drug study through follow up that would interfere with this trial
  • Subject who falls into high risk group on Caprini Risk Assessment for deep vein thrombosis (DVT) and requires Lovenox (Enoxaparin)
  • Subject without a definitive HER2 test according to ASCO/CAP guidelines

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03463954

Layout table for location contacts
Contact: Eugene Bajorinas, MBA 3122667200 ebajorinas@novianhealth.com
Contact: Marti DeLay 3122667200 mdelay@novianhealth.com

Sponsors and Collaborators
Novian Health Inc.
Layout table for investigator information
Principal Investigator: Barbara Schwartzberg, MD Rose Medical Center
Layout table for additonal information
Responsible Party: Novian Health Inc.
ClinicalTrials.gov Identifier: NCT03463954    
Other Study ID Numbers: BR-003
First Posted: March 13, 2018    Key Record Dates
Last Update Posted: March 3, 2021
Last Verified: March 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Keywords provided by Novian Health Inc.:
less than or equal to 15 mm
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases